<DOC>
	<DOCNO>NCT02545972</DOCNO>
	<brief_summary>This study investigate use tacrolimus extend release stable patient undergone heart transplant . All patient receive study medication free charge 1 year duration study .</brief_summary>
	<brief_title>Once-a-day Tacrolimus Conversion Study : The OneTAC Trial</brief_title>
	<detailed_description>Tacrolimus extensively study solid organ transplantation . It FDA approve heart transplant recipient twice day formulation ( Prograf brand name , well generic formulation ) . A modified release formulation available FDA approve kidney transplant recipient ( Astagraf , Astellas Pharmaceutical ) , approve heart transplant patient . In study investigator study 100 patient stable twice day Tacrolimus convert subject day modify release Tacrolimus . The investigator observe patient 1 year follow switch ass safety efficacy heart transplant population .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Adult , age 18 high Heart transplant recipient least 365 day posttransplant time study screen Informed consent available Willingness return study visit , clinically indicate bloodwork On tacrolimusbased chronic immunosuppression . Selfidentified ethnic group provide Prior heart solid organ transplant Less 365 day posttransplant study screen Receiving cyclosporine base immunosuppression calcineurin inhibitor free regimen Concurrent kidney solid organ Inability provide inform consent More 15 year posttransplant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>immunosuppression</keyword>
</DOC>